Regeneration Technologies Inc. (RTIX, Financial) filed Quarterly Report for the period ended 2012-06-30.
Rti Biologics Inc. has a market cap of $205.9 million; its shares were traded at around $3.82 with a P/E ratio of 20.5 and P/S ratio of 1.2.
Marketing, General and Administrative Expenses. Marketing, general and administrative expenses increased $108,000, or 0.8%, to $14.3 million for the three months ended June 30, 2012 from $14.2 million for the three months ended June 30, 2011. Marketing, general and administrative expenses decreased as a percentage of revenues from 32.6% for the three months ended June 30, 2011 to 31.6% for the three months ended June 30, 2012. The increase in expense was primarily due to an increase in variable compensation expense of $550,000, partially offset by decreases in legal expenses of $105,000 and $250,000 favorable foreign currency exchange fluctuations due to a 10.7% increase in the value of the U.S. dollar versus the Euro, as compared to the prior year period.
Research and Development Expenses. Research and development expenses increased by $864,000, or 34.9%, to $3.3 million for the three months ended June 30, 2012 from $2.5 million for the three months ended June 30, 2011. As a percentage of revenues, research and development expenses increased from 5.7% for the three months ended June 30, 2011 to 7.4% for the three months ended June 30, 2012. The increase was primarily due to higher research study related expenses of $739,000.
Marketing, General and Administrative Expenses. Marketing, general and administrative expenses increased $573,000, or 2.0%, to $28.7 million for the six months ended June 30, 2012 from $28.1 million for the six months ended June 30, 2011. Marketing, general and administrative expenses decreased as a percentage of revenues from 33.4% for the six months ended June 30, 2011 to 32.2% for the six months ended June 30, 2012. The increase in expense was primarily due to an increase in variable compensation expense of $1.3 million, partially offset by decreases in legal of $323,000 and lower expenses related to our foreign operations of $620,000 of which $327,000 is due to favorable foreign currency exchange fluctuations due to a 7.5% increase in the value of the U.S. dollar versus the Euro, as compared to the prior year period.
Research and Development Expenses. Research and development expenses increased by $1.3 million, or 26.0%, to $6.2 million for the six months ended June 30, 2012 from $4.9 million for the six months ended June 30, 2011. As a percentage of revenues, research and development expenses increased from 5.8% for the six months ended June 30, 2011 to 6.9% for the six months ended June 30, 2012. The increase was primarily due to higher research study related expenses of $1.0 million.
Read the The complete Report
Rti Biologics Inc. has a market cap of $205.9 million; its shares were traded at around $3.82 with a P/E ratio of 20.5 and P/S ratio of 1.2.
Highlight of Business Operations:
International revenuesInternational revenues include distributions from our foreign affiliates as well as domestic export revenues. International revenues increased $504,000, or 9.2% %, to $6.0 million for the three months ended June 30, 2012 compared to $5.5 million for the three months ended June 30, 2011. International revenues increased primarily as a result of higher domestic export revenues of $1.0 million, offset by a decrease in total international revenues of $527,000 due to a 10.7% increase in the value of the U.S. dollar versus the Euro, as compared to the prior year period.Marketing, General and Administrative Expenses. Marketing, general and administrative expenses increased $108,000, or 0.8%, to $14.3 million for the three months ended June 30, 2012 from $14.2 million for the three months ended June 30, 2011. Marketing, general and administrative expenses decreased as a percentage of revenues from 32.6% for the three months ended June 30, 2011 to 31.6% for the three months ended June 30, 2012. The increase in expense was primarily due to an increase in variable compensation expense of $550,000, partially offset by decreases in legal expenses of $105,000 and $250,000 favorable foreign currency exchange fluctuations due to a 10.7% increase in the value of the U.S. dollar versus the Euro, as compared to the prior year period.
Research and Development Expenses. Research and development expenses increased by $864,000, or 34.9%, to $3.3 million for the three months ended June 30, 2012 from $2.5 million for the three months ended June 30, 2011. As a percentage of revenues, research and development expenses increased from 5.7% for the three months ended June 30, 2011 to 7.4% for the three months ended June 30, 2012. The increase was primarily due to higher research study related expenses of $739,000.
Marketing, General and Administrative Expenses. Marketing, general and administrative expenses increased $573,000, or 2.0%, to $28.7 million for the six months ended June 30, 2012 from $28.1 million for the six months ended June 30, 2011. Marketing, general and administrative expenses decreased as a percentage of revenues from 33.4% for the six months ended June 30, 2011 to 32.2% for the six months ended June 30, 2012. The increase in expense was primarily due to an increase in variable compensation expense of $1.3 million, partially offset by decreases in legal of $323,000 and lower expenses related to our foreign operations of $620,000 of which $327,000 is due to favorable foreign currency exchange fluctuations due to a 7.5% increase in the value of the U.S. dollar versus the Euro, as compared to the prior year period.
Research and Development Expenses. Research and development expenses increased by $1.3 million, or 26.0%, to $6.2 million for the six months ended June 30, 2012 from $4.9 million for the six months ended June 30, 2011. As a percentage of revenues, research and development expenses increased from 5.8% for the six months ended June 30, 2011 to 6.9% for the six months ended June 30, 2012. The increase was primarily due to higher research study related expenses of $1.0 million.
Read the The complete Report
